TY - JOUR
T1 - Chronic dialysis patients with infectious spondylodiscitis have poorer outcomes than non-dialysis populations
AU - Kuo, George
AU - Sun, Wei Chiao
AU - Lu, Yueh An
AU - Chen, Chao Yu
AU - Kao, Huang Kai
AU - Lin, Yujr
AU - Chen, Yung Chang
AU - Hung, Cheng Chieh
AU - Tian, Ya Chung
AU - Hsu, Hsiang Hao
N1 - Publisher Copyright:
© 2018 Kuo et al.
PY - 2018/2/13
Y1 - 2018/2/13
N2 - Purpose: Infectious spondylodiscitis is a serious disease that can lead to permanent neurological deficit. Because there were only a few case reports or series featuring infectious spondylodiscitis in chronic dialysis patients, we investigated the epidemiology and outcome in the chronic dialysis patients versus general population. Materials and methods: We retrospectively identified chronic dialysis patients admitted for infectious spondylodiscitis between January 2002 and December 2015. A total of 105 chronic dialysis patients were included, and we performed a 1:2 case–control match on propensity score in non-dialysis patients with infectious spondylodiscitis. The demographic features, clinical manifestation, infection focus, and disease outcome were recorded. Results: A total of 302 patients entered the final analysis. Chronic dialysis patients less frequently had fever (34.3%), and in the majority, bacterial entry was through dialysis vascular access (30.5%). Methicillin-resistant Staphylococcus aureus (MRSA) comprised the majority of causative pathogen. The chronic dialysis group had longer hospital stay, higher in-hospital mortality, and higher 1-year mortality. The odds ratio of in-hospital mortality was 2.20 compared with the non-dialysis group. Conclusions: The study highlighted poorer outcome and high frequency of resistant Staphylococcus of infectious spondylodiscitis in chronic dialysis patients. Therefore, high vigilance, prompt recognition, and empiric coverage of MRSA will be important in the management of infectious spondylodiscitis in chronic dialysis patients.
AB - Purpose: Infectious spondylodiscitis is a serious disease that can lead to permanent neurological deficit. Because there were only a few case reports or series featuring infectious spondylodiscitis in chronic dialysis patients, we investigated the epidemiology and outcome in the chronic dialysis patients versus general population. Materials and methods: We retrospectively identified chronic dialysis patients admitted for infectious spondylodiscitis between January 2002 and December 2015. A total of 105 chronic dialysis patients were included, and we performed a 1:2 case–control match on propensity score in non-dialysis patients with infectious spondylodiscitis. The demographic features, clinical manifestation, infection focus, and disease outcome were recorded. Results: A total of 302 patients entered the final analysis. Chronic dialysis patients less frequently had fever (34.3%), and in the majority, bacterial entry was through dialysis vascular access (30.5%). Methicillin-resistant Staphylococcus aureus (MRSA) comprised the majority of causative pathogen. The chronic dialysis group had longer hospital stay, higher in-hospital mortality, and higher 1-year mortality. The odds ratio of in-hospital mortality was 2.20 compared with the non-dialysis group. Conclusions: The study highlighted poorer outcome and high frequency of resistant Staphylococcus of infectious spondylodiscitis in chronic dialysis patients. Therefore, high vigilance, prompt recognition, and empiric coverage of MRSA will be important in the management of infectious spondylodiscitis in chronic dialysis patients.
KW - End stage renal disease
KW - Infectious spondylodiscitis
KW - Methicillin-resistant Staphylococcus aureus
KW - Mortality
KW - Pyogenic spondylodiscitis
UR - http://www.scopus.com/inward/record.url?scp=85042163952&partnerID=8YFLogxK
U2 - 10.2147/TCRM.S153546
DO - 10.2147/TCRM.S153546
M3 - 文章
AN - SCOPUS:85042163952
SN - 1176-6336
VL - 14
SP - 257
EP - 263
JO - Therapeutics and Clinical Risk Management
JF - Therapeutics and Clinical Risk Management
ER -